Safety and efficacy of a bilayered skin construct in full-thickness surgical wounds.
This was a prospective, randomized, controlled clinical trial assessing the safety and efficacy of a living bilayered skin construct (BSC; Organogenesis, Canton, MA) in treating full-thickness surgical excision wounds. We enrolled 31 patients needing excision of a non-melanoma skin cancer. The patients consisted of 18 females and 13 males, with an average age of 67 years (range: 44 to 84 years). Patients were randomized to either receive a single application of BSC or to heal by secondary intention. Endpoints to assess efficacy included time to complete wound closure, intensity and duration of post-operative pain, cosmetic appearance, patient satisfaction, and quality of the healed wound. Endpoints to assess safety included infection at the wound site and rejection of the BSC. Findings indicate that BSC is safe in the post-operative treatment of acute surgical wounds for removal of non-melanoma skin cancer. The data also suggest that BSC may facilitate management by decreasing post-operative pain. It is unclear whether or not BSC decreases healing time of acute wounds or results in a better cosmetic outcome.
Donohue
Kevin G
KG
Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Providence, RI 02906, USA.
Carson
Polly
P
Iriondo
Manuel
M
Zhou
Linda
L
Saap
Liliana
L
Gibson
Kathleen
K
Falanga
Vincent
V
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001913:Bowen's Disease / Q000601:surgery; D002280:Basal Cell Carcinoma / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000601:surgery; D003094:Collagen; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000601:surgery*; D017768:Skin, Artificial; D016896:Treatment Outcome; D014945:Wound Healing
C117898:Apligraf; D003094:Collagen